Condition: Hypertension,Essential · Sponsor: Boryung Pharmaceutical Co., Ltd
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide, based on fimasartan. (Stage 1). Also, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)
This description comes directly from the study's public registry record.
MyungSook Hong · +8227088238 · mshong@boryung.co.kr
JiYeon Kim · +8227088128 · jiyeonkim@boryung.co.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Bundang Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05413057